Terns Pharmaceuticals, Inc.
TERN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $1,000 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $1,000 |
| % Margin | – | – | – | 100% |
| R&D Expenses | $70,112 | $63,497 | $39,617 | $31,311 |
| G&A Expenses | $31,759 | $39,061 | $22,412 | $19,549 |
| SG&A Expenses | $31,759 | $39,061 | $22,412 | $19,549 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $101,871 | $102,558 | $62,029 | $50,860 |
| Operating Income | -$101,871 | -$102,558 | -$62,029 | -$49,860 |
| % Margin | – | – | – | -4,986% |
| Other Income/Exp. Net | $13,278 | $12,587 | $2,042 | $210 |
| Pre-Tax Income | -$88,593 | -$89,971 | -$59,987 | -$49,650 |
| Tax Expense | $260 | $239 | $358 | $508 |
| Net Income | -$88,853 | -$90,210 | -$60,345 | -$50,158 |
| % Margin | – | – | – | -5,015.8% |
| EPS | -1.12 | -1.27 | -1.67 | -1.98 |
| % Growth | 11.8% | 24% | 15.7% | – |
| EPS Diluted | -1.12 | -1.27 | -1.67 | -1.98 |
| Weighted Avg Shares Out | 79,507 | 71,259 | 36,033 | 25,269 |
| Weighted Avg Shares Out Dil | 79,507 | 71,259 | 36,033 | 25,269 |
| Supplemental Information | – | – | – | – |
| Interest Income | $13,289 | $12,901 | $2,110 | $170 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $896 | $881 | $1,032 | $512 |
| EBITDA | -$100,975 | -$101,677 | -$60,997 | -$49,348 |
| % Margin | – | – | – | -4,934.8% |